ABEO

Healthcare Biotechnology

Abeona Therapeutics Inc.

$5.03

-0.01 -0.20% today

Price History

Not enough data

Key Stats

Market Cap

287.64M

Avg Volume

1.43M

EPS

-$1.18

52W High

$7.65

52W Low

$4.00

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-24.24

P/B Ratio

2.25

P/S Ratio

11.27

EV/EBITDA

-1.99

EV/Revenue

6.30

Margins

Gross Margin (39.9%)

Operating Margin (120.0%)

Net Margin (246.4%)

EBITDA Margin 0.0%

Growth & Returns

Revenue Growth (YoY)

2745.0%

Return on Equity

(43.1%)

Return on Assets

(24.6%)

Liquidity & Leverage

Current Ratio

6.63

Quick Ratio

6.32

Debt / Equity

0.16

Total Cash

146.83M

Total Debt

19.87M

About

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.